Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates

Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India and is now prioritizing meeting the demand in the world’s most populous country, with a population of 1.4 billion. Eli Lilly launched Mounjaro in India in March of this year, ahead of its rival Novo Nordisk’s (NYSE:NVO) anticipated entry with Wegovy.

According to data from the research firm PharmaTrac, Mounjaro has sold over 81,570 units in India and made ~$2.76 million in revenue as of May. The drug’s sales increased by 60% between April and May, with the 5mg dose showing a 145% sales surge in May compared to April, which shows both strong patient adherence and demand. Mounjaro is currently available in India at a relatively cheaper price when compared to imported alternatives like Novo Nordisk’s Wegovy.

The introduction of Mounjaro comes as India faces a rising burden of obesity and diabetes. A government survey conducted between 2019 and 2021 revealed that 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, which is up from 20.6% and 19% respectively in 2015-2016. Furthermore, the International Diabetes Federation projects that the number of adults with diabetes in India will increase from 74.2 million in 2021 to over 124 million by 2045.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals globally.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.